
Natco to buy U.S. firm Dash in $18-mn deal
The Hindu
Drugmaker Natco Pharma is planning to acquire U.S. firm Dash Pharmaceuticals LLC, for a cash consideration of $18 million, through one of its subsidiaries. The acquisition, which is likely to be compl
Drugmaker Natco Pharma is planning to acquire U.S. firm Dash Pharmaceuticals LLC, for a cash consideration of $18 million, through one of its subsidiaries.
The acquisition, which is likely to be completed by January, will provide a front-end to engage with its customers directly in the U.S., the largest pharmaceutical market in the world, Natco Pharma said on Tuesday.
In a filing with the stock exchange, following a meeting of the Board, Natco said it proposed to enter into an agreement to acquire 100% stake in Dash Pharmaceuticals. The transaction will be subject to satisfactory completion of due diligence, execution of definitive agreements and compliance with statutory requirements.

India’s trade data for November reveals continued resilience in exports despite mounting U.S. tariffs on several key products. This is particularly significant given that the U.S. remains India’s largest export partner by a substantial margin. Interestingly, overall exports have not only grown, but shipments specifically to the U.S. have also rebounded.












